Author Interviews, Genetic Research, Lancet, Ophthalmology / 26.02.2025

MedicalResearch.com Interview with: [caption id="attachment_66831" align="alignleft" width="125"]Professor Michel Michaelides BSc MB BS MD(Res) FRCOphth FACSProfessor of Ophthalmology and Consultant Ophthalmic Surgeon UCL Institute of Ophthalmology and Moorfields Eye Hospital  Prof. Michaelides[/caption] Professor Michel Michaelides BSc MB BS MD(Res) FRCOphth FACS Professor of Ophthalmology and Consultant Ophthalmic Surgeon UCL Institute of Ophthalmology and Moorfields Eye Hospital     MedicalResearch.com: What is the background for this study?
  • Leber congenital amaurosis (LCA) is a rare inherited retinal disease (IRD) that causes the degeneration of the cone and rod cells in the retina. It is characterized by severe vision loss at birth/early infancy and is one of the commonest causes of legal blindness in childhood. There is a wide range of severity at birth/early infancy, ranging from light perception to useful central vision; with variable rate of progression over time, LCA is estimated to occur in about 1 in 33,000 people. There are more than 30 genes that cause LCA.
  • LCA associated with genetic deficiency of AIPL1 is one of the most severe forms of LCA – resulting in profound visual loss from birth (often light perception only) and rapidly progressive retinal degeneration.
  • The study sought to evaluate whether early intervention by gene supplementation therapy in children with LCA associated with AIPL1 was safe and could improve outcomes.
Author Interviews, Gender Differences, JAMA, University of Michigan / 14.02.2025

MedicalResearch.com Interview with: [caption id="attachment_66556" align="alignleft" width="200"]Farrah Madanay, PhDPostdoctoral Research Fellow Center for Bioethics and Social Sciences in Medicine Michigan Medicine University of Michigan Dr. Madanay[/caption] Farrah Madanay, PhD Postdoctoral Research Fellow Center for Bioethics and Social Sciences in Medicine Michigan Medicine University of Michigan MedicalResearch.com: What is the background for this study? Response: Patients are increasingly using online forums to evaluate their physicians, with not only star ratings but also written narrative reviews. These reviews tend to fall into two dimensions: interpersonal manner, which includes comments about the physician’s attitude, behavior, and communication; and technical competence, which includes comments about the physician’s knowledge, skill, and outcomes. These two dimensions are important for patient-centered care and align with research from social psychology. Whereas prior studies have revealed gender differences in workplace assessments and overall star ratings of physicians, little is known about physician gender differences in patients’ online written reviews. We were curious whether physician gender differences were prevalent in patients’ written reviews and consistent across physician specialties, from generalists, like primary care physicians, to proceduralists, like surgeons. We collected physician profile, rating, and review data from one of the largest commercial physician rating and review websites. We focused on physicians from three primary care specialties (family medicine, internal medicine, and pediatrics), and three surgical specialties (general surgery; orthopedic surgery; and cosmetic, plastic, and reconstructive surgery). Our final sample included 345,053 online reviews received by 167,150 U.S. physicians between 2015 and 2020. We used hand-coded reviews to train an advanced natural language processing algorithm to classify all reviews for the presence and valence of patients’ comments of physicians’ interpersonal manner and technical competence. We then conducted multilevel logistic regressions to analyze differences by female or male physician gender in interpersonal manner and technical competence comments and whether those comments were associated with review star ratings.
Allergies, Author Interviews, NEJM, Pediatrics / 11.02.2025

Editor's note:  Do not attempt immunotherapy for peanut or other allergens without the express direction of your health care provider. Life-threatening reactions may occur. MedicalResearch.com Interview with: [caption id="attachment_66501" align="alignleft" width="130"]Scott H. Sicherer, MDElliot and Roslyn Jaffe Professor of Pediatrics, Allergy and Immunology Director, Jaffe Food Allergy Institute Division Chief, Pediatric Allergy Medical Director, Clinical Research Unit Icahn School of Medicine at Mount Sinai Jack and Lucy Clark Department of Pediatrics Mount Sinai Kravis Children’s Hospital New York, NY 10029 Dr. Sicherer[/caption] Scott H. Sicherer, MD Elliot and Roslyn Jaffe Professor of Pediatrics, Allergy and Immunology Director, Jaffe Food Allergy Institute Division Chief, Pediatric Allergy Medical Director, Clinical Research Unit Icahn School of Medicine at Mount Sinai Jack and Lucy Clark Department of Pediatrics Mount Sinai Kravis Children’s Hospital New York, NY 10029 MedicalResearch.com: What is the background for this study? Response: About 2% of people have a peanut allergy.  While many of them are exquisitely allergic to tiny amounts, about half can tolerate a half a peanut kernel or more before they have symptoms, although the symptoms can be severe. Current studies and FDA approved treatments for peanut allergy have typically focused on people reacting to about half a peanut or less.  We thought that those with higher threshold may be more easily treated. We focused on children ages 4-14 years who we identified through a medically supervised feeding test as having allergic reactions from 443 to 5043 mg of peanut protein.  A peanut kernel is about 250 mg of peanut protein. The 73 children were randomized to a treatment (oral immunotherapy, OIT) using home-measured, store bought peanut butter versus continuing the standard of care, avoidance.  OIT involves medically supervised dosing going from a small amount to gradually increasing larger amounts.  The increases are done under direct allergist supervision, then the tolerated dose is taken at home daily. Families are given instructions about avoiding things that can cause a reaction from dosing, such as exercise after a dose, and to skip dosing for illness.  Dosing can cause reactions and they were instructed on how to recognize and treat any such reactions.   We did increases every 2 months. Most of the children (62) stayed in the study to be tested after the period of treatment, that aimed for having a level tablespoon of peanut butter each day. All of the treated children who completed testing (32) were able to eat 9 grams of peanut.  Only 3 of 30 who continued to avoid peanut were able to do this.
Author Interviews, JAMA, Salt-Sodium, Stroke / 09.02.2025

MedicalResearch.com Interview with: Xiong Ding, MPH School of Public Health Wuhan University Wuhan, China MedicalResearch.com: What is the background for this study? Response: Stroke is one of the leading causes of death and long-term disability worldwide, particularly in low- and middle-income countries. Patients who have previously experienced a stroke are at high risk of recurrence, and in China, this risk is even higher than the global average. It is well established that high blood pressure is a major risk factor for stroke recurrence, and lowering blood pressure is an effective preventive strategy. Salt substitutes, which replace part of sodium chloride with potassium chloride, have been shown to lower blood pressure by reducing sodium intake and increasing potassium intake. However, before our study, there was limited direct evidence demonstrating whether salt substitutes could reduce the risk of stroke recurrence and death. Therefore, we conducted this research as part of the Salt Substitute and Stroke Study (SSaSS), specifically focusing on stroke survivors to determine the long-term health effects of salt substitution in this high-risk population.
Author Interviews, Cannabis, JAMA, Pediatrics, UCSD / 30.01.2025

MedicalResearch.com Interview with: [caption id="attachment_66243" align="alignleft" width="150"]John Bellettiere, PhDAssistant Adjunct Professor Herbert Wertheim School of Public Health & Human Longevity Science University of California, San Diego Dr. Bellettiere[/caption] John Bellettiere, PhD Assistant Adjunct Professor Herbert Wertheim School of Public Health & Human Longevity Science University of California, San Diego MedicalResearch.com: What is the background for this study? Response:  Smoking is the most common method of cannabis use and generates harmful emissions.  Cannabis is often smoked indoors, which exposes non-smokers, including children, to these emissions. Our research analyzed in-home cannabis smoking practices to determine if there is an association between this behavior and the detection of cannabis biomarkers in children.
Author Interviews, Cannabis, Cognitive Issues, JAMA, Memory, Mental Health Research / 28.01.2025

MedicalResearch.com Interview with: [caption id="attachment_66219" align="alignleft" width="200"]Joshua Gowin PhDAssistant Professor, Radiology Anschutz Medical Campus University of Colorado  Dr. Gowin[/caption] Joshua Gowin PhD Assistant Professor, Radiology Anschutz Medical Campus University of Colorado  MedicalResearch.com: What is the background for this study? Response: Many people want to know how cannabis affects their brain and cognitive abilities. Previous studies have shown that cannabis use can impair learning and verbal memory function. Some evidence has shown that cannabis use is associated with smaller volume of areas of the prefrontal cortex. Our study investigated how cannabis use is associated with brain function. We examined brain function across 7 tasks in 1,000 adults. 88 of them had used cannabis over 1,000 times in their lives.
Author Interviews, Cannabis, JAMA / 25.01.2025

MedicalResearch.com Interview with: [caption id="attachment_66106" align="alignleft" width="200"]Silvia S. Martins, MD, PhDAssociate Dean for Faculty Professor of Epidemiology Director, Substance Use Epidemiology Unit Co-Director, Substance Abuse Epidemiology T32 Program Department of Epidemiology Columbia University Mailman School of Public Health New York, NY Dr. Martins[/caption] Silvia S. Martins, MD, PhD Associate Dean for Faculty Professor of Epidemiology Director, Substance Use Epidemiology Unit Co-Director, Substance Abuse Epidemiology T32 Program Department of Epidemiology Columbia University Mailman School of Public Health New York, NY MedicalResearch.com: What is the background for this study? Response: Much has been speculated on whether the enactment of medical and recreational cannabis laws can have a role in decreasing prescriptions for opioid pain relievers, opioid use and misuse, opioid use disorder, and overdose in the U.S. However, findings on the associations of medical cannabis laws alone and recreational cannabis las + medical cannabis laws with opioid-related outcomes are mixed. By the end of 2019, 32 U.S. states had adopted medical marijuana laws (MCL) alone. All states that went on to adopt recreational marijuana laws (RCL) had previously adopted an MCL.
Author Interviews, Cancer Research, NEJM, NIH, OBGYNE / 05.12.2024

MedicalResearch.com Interview with: [caption id="attachment_65321" align="alignleft" width="92"]Diana W. Bianchi, M.D.Senior Investigator Center for Precision Health Research Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Dr. Bianchi[/caption] Diana W. Bianchi, M.D. Senior Investigator Center for Precision Health Research Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health MedicalResearch.com: What is the background for this study? Response: The ability of prenatal cell-free DNA (cfDNA) sequencing to incidentally detect maternal cancers has been demonstrated by several retrospective studies from commercial or national laboratories. However, there are no standardized approaches to the identification and medical management of prenatal screening results that might indicate a maternal cancer. We sought to prospectively identify DNA sequencing patterns and other biomarkers that could distinguish which women with nonreportable or unusual cfDNA sequencing results had cancer and to determine the best approach for diagnostic work-up of pregnant people who receive these results.
Author Interviews, Cannabis, JAMA, Mental Health Research / 22.11.2024

MedicalResearch.com Interview with: [caption id="attachment_64963" align="alignleft" width="200"]Belén Blasco Belén Blasco[/caption] Belén Blasco PhD Student in Neuroscience - MD Psychiatry Clinical and Translational Sciences (CaTS) Lab Integrated Program in Neuroscience McGill University | Douglas Research Centre Montreal, Canada MedicalResearch.com: What is the background for this study? Response: Our research is centered on uncovering the early brain changes that might contribute to psychosis development. Using innovative brain imaging techniques, we aimed to measure synapsis in individuals with early psychotic symptoms or who are considered at high clinical risk. Synapses are the crucial points of connection between neurons, allowing communication across the brain. A key aspect of our study was to understand how lifestyle factors, like cannabis use, might impact these brain changes, particularly since cannabis consumption has been associated with an increased risk of developing psychosis in young people.
Author Interviews, Health Care Systems, JAMA, Pharmacology, University of Pittsburgh / 31.10.2024

MedicalResearch.com Interview with: [caption id="attachment_64457" align="alignleft" width="200"]Dr. Katie Suda Dr. Suda[/caption] Katie J. Suda, PharmD, M.S., FCCP Professor of medicine with tenure Associate Director, Center for Pharmaceutical Policy and Prescribing University of Pittsburgh School of Medicine MedicalResearch.com: What is the background for this study? Response: Our pharmaceutical supply chain is global where the manufacturing process for one drug may occur in multiple countries. Sometimes there are breakdowns in the pharmaceutical supply chain which may threaten access to medicines. Breakdowns in the supply chain occur for medicines manufactured in the U.S. and by international partners. While breakdowns in the supply chain occur for hundreds of drugs each year, not all result in a decrease in available supply (a “drug shortage”) because of action taken by manufacturers, pharmacies and drug regulators (e.g., the U.S. Food and Drug Administration [FDA]). Drug shortages are a critical concern to public health as pharmacies, clinicians, and patients struggle to identify safe and effective alternatives. In addition, drug shortages have been associated with adverse patient outcomes and medication safety events. Recently, drug shortages have gotten worse with shortages occurring with increasing frequency and lasting longer. There has also been a shift in the types of medicines in shortage from drugs primarily used in hospitals, such as injectables, to oral medicines frequently used to manage outpatient conditions. Countries have different regulatory authority and policy which may impact how drug supply chain breakdowns result in drug shortages. We wanted to know if there are differences between the U.S. and Canada in the frequency that national drug shortages occur after supply chain breakdowns are reported in both countries. Canada is a good comparator to the U.S. because Canada has similar drug regulatory standards and manufacturing inspections. Prescription drug coverage is also similar for the two countries where half of prescriptions are reimbursed through public insurance and half through private insurance and out-of-pocket.
Author Interviews, Diabetes, Kidney Disease, Nature, Semaglutide / 31.10.2024

MedicalResearch.com Interview on publication of: [caption id="attachment_64443" align="alignleft" width="200"]Prof. dr. H.J. (Hiddo) Lambers HeerspinkClinical Pharmacologist Faculty of Medical Sciences University of Groningen Prof. Heerspink[/caption] Prof. dr. H.J. (Hiddo) Lambers Heerspink Clinical Pharmacologist Faculty of Medical Sciences University of Groningen MedicalResearch.com: What is the background for this study? What are the main findings? Response: The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. The amount of protein in their urine decreased, as did the degree of inflammation of their kidneys and their blood pressure. Hiddo L. Heerspink got the idea for this study at the beginning of the corona pandemic. Earlier, he had discovered that another class of drugs against diabetes-2, the so-called SGLT2 inhibitors also appeared to work well for patients with chronic kidney damage without diabetes. He therefore wanted to investigate whether semaglutide would also work positively for patients with chronic kidney disease and obesity.
Author Interviews, COVID -19 Coronavirus, JAMA, OBGYNE, Pediatrics / 16.10.2024

MedicalResearch.com Interview with: [caption id="attachment_64046" align="alignleft" width="200"]Eleni G. Jaswa, MD, MScAssistant Professor, Ob/Gyn, Reproductive Science UCSF Dr. Jaswa[/caption] Eleni G. Jaswa, MD, MSc Assistant Professor, Ob/Gyn, Reproductive Science UCSF MedicalResearch.com: What is the background for this study? Response: Some infections during pregnancy have been associated with abnormal neurodevelopment in children. This is likely due to the infection itself, or the maternal immune system response to infection. We sought to determine whether maternal COVID-19 infection during pregnancy, a now common occurrence, was associated with changes in children's neurodevelopment out to 24-months-old, compared to control children not exposed to maternal COVID-19 in utero.
Author Interviews, JAMA, Pharmaceutical Companies / 11.10.2024

MedicalResearch.com Interview with: [caption id="attachment_63939" align="alignleft" width="200"]David-Dan Nguyen MDCM MPHDoctoral Student Institute of Health Policy Management and Evaluation and Resident Physician Division of Urology University of Toronto Dr. Nguyen[/caption]

David-Dan Nguyen MDCM MPH Doctoral Student Institute of Health Policy Management and Evaluation and Resident Physician Division of Urology University of Toronto

MedicalResearch.com: What is the background for this study? Response: Peer reviewers are crucial to the academic publishing process. While there’s been significant scrutiny of potential conflicts of interest among authors and editors of major journals, the potential for conflicts of interest among peer reviewers has been relatively unexplored. As such, our study aimed to quantify and characterize industry payments made to peer reviewers of top medical journals—The BMJ, JAMA, The Lancet, and The New England Journal of Medicine—to better understand the extent of these financial relationships. 
Author Interviews, Cancer Research, JAMA, Microbiome, NYU/NYMC / 01.10.2024

MedicalResearch.com Interview with: [caption id="attachment_63665" align="alignleft" width="211"]Jiyoung Ahn, PhDProfessor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center  NYU Langone Health Smilow Research Building New York, NY 10016 Prof. Ahn[/caption] Jiyoung Ahn, PhD Professor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center NYU Langone Health Smilow Research Building New York, NY 10016 MedicalResearch.com: What is the background for this study? What are the main findings? Response: We found that oral bacterial species are linked to a collective 50% increased risk of developing head and neck squamous cell carcinoma (HNSCC). Some of these microbes have previously been shown to contribute to periodontal disease, a serious gum infection that can erode the jawbone and the soft tissues surrounding the teeth.
Aging, Author Interviews, BMJ, Heart Disease, Statins / 11.09.2024

MedicalResearch.com Interview with: [caption id="attachment_63267" align="alignleft" width="146"]Borislava Mihaylova, DPhilAssociate Professor & Senior Health Economist Nuffield Department of Population Health, University of Oxford, UK & Professor of Health Economics Wolfson Institute of Population Health Queen Mary University of London, UK Prof. Mihaylova[/caption] Borislava Mihaylova, DPhil Associate Professor & Senior Health Economist Nuffield Department of Population Health, University of Oxford, UK & Professor of Health Economics Wolfson Institute of Population Health Queen Mary University of London, UK MedicalResearch.com: What is the background for this study? Response: Despite high risks of heart disease and stroke in people over 70 years old and high need for preventive treatment such as statins, fewer older people use statins [compared to middle-aged people]. This, at least in part, is likely due to fewer older people, particularly those without previous heart attacks and strokes, included in the randomized studies of statin treatment. This has led to more limited evidence among them with larger uncertainty. Thus, we set to re-examine the value of statin treatment using the latest evidence and contemporary population data.
Anemia, Author Interviews, JAMA, OBGYNE / 23.08.2024

[caption id="attachment_60875" align="alignleft" width="133"]Esa M. Davis, M.D., M.P.H , F.A.A.F.P Professor of Medicine and Family and Community Medicine Associate Vice President of Community Health and Senior Associate Dean of pPopulation Health and Community Medicine University of Maryland School of Medicine Dr. Davis joined the U.S. Preventive Services Task Force in January 2021 Dr. Davis[/caption] Esa M. Davis, M.D., M.P.H , F.A.A.F.P Professor of Medicine and Family and Community Medicine Associate Vice President of Community Health and Senior Associate Dean of pPopulation Health and Community Medicine University of Maryland School of Medicine Dr. Davis joined the U.S. Preventive Services Task Force in January 2021     MedicalResearch.com: What is the background for this study? What are the main findings? Response: Iron is important to overall health, and people need more iron when they are pregnant. This can make pregnant people at increased risk for iron deficiency, which can progress to anemia and cause complications for both moms and their babies. After reviewing the latest available research, the Task Force found that there is not enough evidence on whether pregnant people who do not have signs or symptoms of iron deficiency or anemia should be screened—or take iron supplements—to improve their health or the health of their baby.  
Author Interviews, Science, Sleep Disorders / 18.08.2024

MedicalResearch.com Interview with: [caption id="attachment_62876" align="alignleft" width="92"]Azahara Oliva PhDAssistant Professor Department of Neurobiology and Behavior Cornell University Dr. Oliva[/caption] Azahara Oliva PhD Assistant Professor Department of Neurobiology and Behavior Cornell University   MedicalResearch.com: What is the background for this study? What are the main findings? Response: The background is that we knew for a while now that neurons work hard to consolidate into memories each experience that we have during the day. But at the same time, it is known that sleep restore activity of our body and physiology. How was that possible? How can the neurons in our brain "work hard" during the time that we are supposed to be restoring our vitals? We found that in between their hard work, during sleep, our neurons take "breaks of activity" so our brain can build memories with precision.
Author Interviews, Brigham & Women's - Harvard, Genetic Research, JAMA, Karolinski Institute, Prostate Cancer / 05.07.2024

MedicalResearch.com Interview with: [caption id="attachment_62249" align="alignleft" width="204"]Anna Plym PhDDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden Department of Epidemiology, Harvard T. H. Chan School of Public Health Department of Urology, Brigham and Women’s Hospital Harvard Medical School, Boston, Massachusetts Dr. Plym[/caption] Anna Plym PhD Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden Department of Epidemiology, Harvard T. H. Chan School of Public Health Department of Urology, Brigham and Women’s Hospital Harvard Medical School, Boston, Massachusetts MedicalResearch.com: What is the background for this study? Response: Prostate cancer is one of the leading causes of cancer death among men, with approximately one third of the deaths occurring before the age of 75 years. There is a need for a better understanding of the risk factors for those early deaths. Our previous research has indicated that inherited factors play a major role.
Author Interviews, Heart Disease, JAMA, Lipids / 03.07.2024

MedicalResearch.com Interview with: [caption id="attachment_62223" align="alignleft" width="150"]Evan A Stein MD PhD FACCCOO/CSO LIB Therapeutics Cincinnati. OH USA 45227 Dr. Stein[/caption] Evan A Stein MD PhD FACC COO/CSO LIB Therapeutics Cincinnati. OH USA 45227 MedicalResearch.com: What is the background for this study? Response: Cardiovascular disease (CVD) remains the main cause of morbidity and mortality worldwide and is increasing in rapidly industrializing countries and is projected to cause more than >20 million deaths annually over the next 15 years. Low-density lipoprotein cholesterol (LDL-C) is well established as a major, easily modifiable, risk factor for CVD. Reductions with statins and, more recently, PCSK9 inhibitors, all agents which directly or indirectly upregulate the LDL receptor and enhance LDL-C clearance, have demonstrated CVD event reductions in cardiovascular outcome trials. Extensive data from these trials, provide a rough estimate that every 40 mg/dL reduction in LDL-C will reduce the risk of major CV cardiovascular events by 22% to 24%. Furthermore, trials with PCSK9 inhibitors added to statins which achieve substantial additional LDL-C reduction show and CVD event reduction remains linear to very low LDL-C levels without signals of adverse events. Based on this body of evidence, recent revisions to national and international guidelines, now advocate for greater LDL-C reductions and lower LDL-C treatment goals, for patients not achieving these goals on statins alone. The current consensus target goal for LDL-C in patients with CVD, or who are at very-high risk for of CVD, is now less than <55 mg/dL, and <70 mg/dL for those at high risk. This global trial of over 900 patients with CVD, or at very or high risk for CVD, on maximally tolerated statins assessed the 52-week efficacy and safety of monthly lerodalcibep.
Author Interviews, Cost of Health Care, JAMA, Kidney Disease, Transplantation / 01.07.2024

MedicalResearch.com Interview with: [caption id="attachment_62111" align="alignleft" width="200"]Amal Trivedi, MD, MPHProfessor of Health Services, Policy & Practice Brown University School of Public Health Prof. Trivedi[/caption] Amal Trivedi, MD, MPH Professor of Health Services, Policy & Practice Brown University School of Public Health MedicalResearch.com: What is the background for this study? Response: On January 1st, 2021, the Centers for Medicare & Medicaid Services (CMS) launched the mandatory End-Stage Renal Disease Treatment Choices (ETC) Model, which randomly assigned approximately 30% of U.S. dialysis facilities and managing clinicians to financial incentives to increase the use of home dialysis and kidney transplantation. The program is set to run through 2027, with financial incentives and penalties increasing as the model progresses. Our study sought to assess the ETC’s effect on these outcomes of interest in the first two years, as well as to examine outcome changes by race, ethnicity and socioeconomic status.
Alzheimer's - Dementia, Author Interviews, JAMA / 22.06.2024

MedicalResearch.com Interview with: [caption id="attachment_62050" align="alignleft" width="150"]Mabel Seto, PhDHarvard Aging Brain Study, Department of Neurology Massachusetts General Hospital, Center for Alzheimer Research and Treatment Department of Neurology Brigham and Women’s Hospital Harvard Medical School Boston, Massachusetts Vanderbilt Memory and Alzheimer’s Center Vanderbilt University Medical Center Nashville, Tennessee Dr. Seto[/caption] Mabel Seto, PhD Harvard Aging Brain Study, Department of Neurology Massachusetts General Hospital, Center for Alzheimer Research and Treatment Department of Neurology Brigham and Women’s Hospital Harvard Medical School, Boston, Massachusetts Vanderbilt Memory and Alzheimer’s Center Vanderbilt University Medical Center Nashville, Tennessee   MedicalResearch.com: What is the background for this study? Response: The background for this study is that individuals with a family history of Alzheimer’s disease (i.e., one or more first-degree relatives) have a higher risk for the disease than individuals that don’t have a family history. Previous studies suggested a preferential maternal inheritance of AD, though they were limited in sample size and statistical power. In our study, we wanted to focus on a larger, cognitively unimpaired sample. Using data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study, a randomized clinical trial aimed at AD prevention, we examined the relationship between a parental history of significant memory impairment as a proxy for AD (as some individuals may not have pursued formal diagnosis) and amyloid-beta burden in the offspring.
Author Interviews, PLoS, Sexual Health / 22.06.2024

MedicalResearch.com Interview with: Karyn Anderson (she/her) PhD Candidate, Evolutionary Anthropology Lab of Dr. Julie Teichroeb University of Toronto, Scarborough MedicalResearch.com: What is the background for this study? What are the main findings? Response: We sought out to determine if there were observations of same-sex sexual behavior in mammals that exist beyond the published record. We found that more people observe same-sex sexual behavior than they publish on it, and this appears to be due to a perception of researchers that same-sex sexual behavior is very rare. We found, however, that it was commonly observed by our survey participants.
Author Interviews, Breast Cancer, Colon Cancer, Genetic Research, JAMA / 20.06.2024

MedicalResearch.com Interview with: [caption id="attachment_62041" align="alignleft" width="150"]Dr. Jeremy L. Davis M.D.Surgical Oncologist Center for Cancer Research Dr. Davis’ research focuses on sporadic and inherited forms of stomach cancer. National Cancer Institute Dr. Davis[/caption] Dr. Jeremy L. Davis M.D. Surgical Oncologist Center for Cancer Research Dr. Davis’ research focuses on sporadic and inherited forms of stomach cancer. National Cancer Institute   MedicalResearch.com: What is the background for this study? Response: Individuals who are born with a CDH1 gene mutation are at increased risk of developing specific cancers in their lifetime. Those cancers are called diffuse-type gastric cancer and lobular breast cancer. The background that is relevant here is that when mutations in this gene were first identified as the cause of inherited forms of these cancers, the estimated lifetime risk of gastric cancer, for instance, was around 60-83%. Because of this very high risk and because gastric cancer is particularly difficult to treat, many experts recommend prophylactic surgery to remove the stomach. In recent years, as we have seen more families who carry a CDH1 gene mutation, we have also observed that gastric cancer rates did not seem quite as high as those risk estimates would have suggested. We sought to re-evaluate lifetime risk of cancer with a large and diverse cohort of individuals throughout North America.
Author Interviews, Genetic Research, Heart Disease, Nature / 14.06.2024

MedicalResearch.com Interview with: [caption id="attachment_61964" align="alignleft" width="136"]Ben Omega Petrazzini, B.Sc.Associate Bioinformatician Ron Do Laboratory Ben Petrazzini[/caption] Ben Omega Petrazzini, B.Sc. Associate Bioinformatician Ron Do Laboratory [caption id="attachment_61965" align="alignleft" width="143"]Ron Do, Ph.D.Professor, Department of Genetics and Genomic Sciences Director, Center for Genomic Data Analytics Associate Director in Academic Affairs, The Charles Bronfman Institute for Personalized Medicine Charles Bronfman Professor in Personalized Medicine Dr. Ron Do[/caption] Ron Do, Ph.D. Professor, Department of Genetics and Genomic Sciences Director, Center for Genomic Data Analytics Associate Director in Academic Affairs, The Charles Bronfman Institute for Personalized Medicine Charles Bronfman Professor in Personalized Medicine Icahn School of Medicine at Mount Sinai     MedicalResearch.com: What is the background for this study? Response: Rare coding variants directly affect protein function and can inform the role of a gene in disease. Discovery of rare coding variant associations for coronary artery disease (CAD) to date have only had limited success. Genetic studies typically use standard phenotyping approaches to classify cases versus controls for CAD. However, this phenotyping approach doesn’t capture disease progression or severity in individuals. We recently introduced an in-silico score for CAD (ISCAD) that tracks CAD progression, severity, underdiagnosis and mortality (Forrest et al. The Lancet, 2023, PMID 36563696). ISCAD was built using a machine learning model trained on clinical data from electronic health records (EHR). Importantly, ISCAD is a quantitative score that measures CAD on a spectrum. The quantitative nature of the score provides an opportunity to discover additional rare coding variant associations that may not have been detected with the standard case-control phenotyping approach. Here in this study, we performed a large-scale rare variant association study in the exome sequences of 604,915 individuals for ISCAD, a machine learning-based score for CAD.
Author Interviews, Critical Care - Intensive Care - ICUs, Heart Disease, Kidney Disease, NEJM / 13.06.2024

MedicalResearch.com Interview with: [caption id="attachment_61951" align="alignleft" width="150"]Prof Giovanni Landoni, MDAssociate Professor Università Vita-Salute San Raffaele Milan, Italy Prof. Landoni[/caption] Prof Giovanni Landoni, MD Associate Professor Università Vita-Salute San Raffaele Milan, Italy MedicalResearch.com: What is the background for this study? Response: Acute kidney injury (AKI) affects approximately 10-15% of hospitalized patients, and up to 50% of intensive care unit (ICU) patients. In cardiac surgery one patient out of three will face AKI during the postoperative period, and this will lead to higher morbidity and mortality. AKI is associated with an elevated risk of chronic kidney disease, as well as, in the most severe cases, with the use of renal replacement therapy, which may double hospitalization costs, reduce quality of life, and increase long-term mortality. So far, no preventive measure with level I of evidence did exist for AKI. The PROTECTION trial is a multinational, randomized, double-blind, placebo-controlled trial, conducted at 22 centers in 3 different countries. We recruited 3,511 adult patients undergoing cardiac surgery with cardiopulmonary bypass to receive an intravenous infusion of amino acids (AA) (Isopuramin 10%, Baxter), at 2g/kg/day up to a maximum 100g/day, or an equivalent dose of placebo (Ringer’s solution), for a maximum of 72 hours. The primary outcome was the incidence of any stage of AKI, according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 creatinine criteria.
Author Interviews, Dermatology, JAMA, Salt-Sodium / 12.06.2024

MedicalResearch.com Interview with: [caption id="attachment_61942" align="alignleft" width="200"]Katrina Abuabara, MD, MA, MSCEAssociate Professor of Dermatology, UCSF Associate Adjunct Professor of Epidemiology UC Berkeley School of Public Health Dr. Abuabar[/caption] Katrina Abuabara, MD, MA, MSCE Associate Professor of Dermatology, UCSF Associate Adjunct Professor of Epidemiology UC Berkeley School of Public Health MedicalResearch.com: What is the background for this study? Response: Eczema (also known as atopic dermatitis) has become increasingly common over recent decades, especially in industrialized countries, suggesting that environmental or lifestyle factors like diet could impact rates of disease. It is well established that sodium, consumed primarily in the form of salt, increases the risk of hypertension and heart disease through pro-inflammatory mechanisms. The role of sodium on other chronic inflammatory conditions like eczema has been less well-studied.
Aging, Author Interviews, Exercise - Fitness, JAMA, USPSTF / 10.06.2024

MedicalResearch.com Interview with: [caption id="attachment_61045" align="alignleft" width="150"]Li Li, M.D., Ph.D., M.P.H. The Walter M. Seward Professor and Chair of Family Medicine University of Virginia (UVA) School of Medicine Director of Population Health at UVA Health Dr. Li Li[/caption] Li Li, M.D., Ph.D., M.P.H Walter M. Seward Professor Chair of Family Medicine Director of population health University of Virginia School of Medicine Editor-in-chief of The BMJ Family Medicine Dr. Li joined the U.S. Preventive Services Task Force in January 2021 MedicalResearch.com: What is the background for this study? What are the main findings of the underlying studies? Response: Falls are the leading cause of injuries in older adults and can lead to serious disability and even death. To help prevent these incidents, the Task Force looked at the current evidence on ways that primary care clinicians can help prevent falls in adults aged 65 and older who live at home and are more likely to fall. We concluded that healthcare professionals should recommend exercise interventions for adults aged 65 and older who are at increased risk for falls. This could include gait, balance, and functional training, as well as strength, resistance, and flexibility training. Clinicians can also talk with their older patients who are most likely to fall about whether additional interventions might be helpful to reduce their risk of falling.
Alcohol, Author Interviews, CMAJ / 03.06.2024

MedicalResearch.com Interview with: [caption id="attachment_61837" align="alignleft" width="125"]Rahel Zewude, MD FRCPCInfectious Diseases and Medical Microbiology, PGY-5 University of Toronto Dr. Zewude[/caption] Rahel Zewude, MD FRCPC Infectious Diseases and Medical Microbiology, PGY-5 University of Toronto MedicalResearch.com: What is the background for this study? Would you describe the syndrome of Auto-brewery syndrome? Response: Auto-brewery syndrome refers to a syndrome where the gut ferments alcohol from carbohydrates leading to high blood alcohol levels and intoxication without any consumption of alcoholic drinks.
AHA Journals, Author Interviews, Blood Pressure - Hypertension, OBGYNE / 29.05.2024

MedicalResearch.com Interview with: [caption id="attachment_61675" align="alignleft" width="150"]Emmanuel Bujold, ReproductionMother and Child Health Unit CHU De Québec-Université Laval Research Center Université Laval Québec, QC Canada Dr. Bujold[/caption] Emmanuel Bujold, Reproduction Mother and Child Health Unit CHU De Québec-Université Laval Research Center Université Laval Québec, QC Canada     MedicalResearch.com: What is the background for this study? Would you briefly describe what is meant by preeclampsia? Response: Preeclampsia is a complication of the second half of pregnancy, manifesting as high blood pressure and renal dysfunction. The only current treatment is to deliver the baby before it becomes complicated by damage to maternal organs or fetal distress. A few years ago, we demonstrated that aspirin started in the 1st trimester can prevent the majority of preeclampsias in pregnant women at risk. It has therefore become urgent to identify pregnant women at risk as early as the 1st trimester.